Amy Newlands

411 total citations
16 papers, 302 citations indexed

About

Amy Newlands is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Immunology and Allergy. According to data from OpenAlex, Amy Newlands has authored 16 papers receiving a total of 302 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 12 papers in Physiology and 4 papers in Immunology and Allergy. Recurrent topics in Amy Newlands's work include Asthma and respiratory diseases (12 papers), Respiratory and Cough-Related Research (8 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (6 papers). Amy Newlands is often cited by papers focused on Asthma and respiratory diseases (12 papers), Respiratory and Cough-Related Research (8 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (6 papers). Amy Newlands collaborates with scholars based in United Kingdom, United States and China. Amy Newlands's co-authors include Kevin Smart, Robert Murdoch, Angela Kelsall, Kimberley Holt, Saifudin Khalid, Rachel Dockry, Ashley Woodcock, John A. Smith, Alison Church and Nanshan Zhong and has published in prestigious journals such as PLoS ONE, Journal of Allergy and Clinical Immunology and European Respiratory Journal.

In The Last Decade

Amy Newlands

16 papers receiving 299 citations

Peers

Countries citing papers authored by Amy Newlands

Since Specialization

Citations

This map shows the geographic impact of Amy Newlands's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Newlands with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Newlands more than expected).

Fields of papers citing papers by Amy Newlands

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Newlands. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Newlands. The network helps show where Amy Newlands may publish in the future.

Co-authorship network of co-authors of Amy Newlands

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Newlands. A scholar is included among the top collaborators of Amy Newlands based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Newlands. Amy Newlands is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Efficacy and safety of GSK3772847 in participants with moderate-to-severe asthma with allergic fungal airway disease: A phase IIa randomized, multicenter, double-blind, sponsor-open, comparative trial 2023 ·PLoS ONE ·(unknown), Courtney Crim, Amy Newlands, (unknown)	12
2	Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial 2016 ·Drugs in R&D ·Chris Kalberg, Dianne M. O’Dell, Dmitry Galkin, Amy Newlands, William A. Fahy	23
3	Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study 2015 ·International Journal of COPD ·(unknown), Nanshan Zhong, Amy Newlands, Alison Church, (unknown)	32
4	Efficacy and safety of fluticasone furoate/vilanterol (50/25 mcg; 100/25 mcg; 200/25 mcg) in Asian patients with chronic obstructive pulmonary disease: a randomized placebo-controlled trial 2015 ·Current Medical Research and Opinion ·Jinping Zheng, (unknown), Jie Wang‐Jairaj, Amy Newlands, Changzheng Wang, Courtney Crim, Nanshan Zhong	18
5	TRPV1 Antagonism in Refractory Chronic Cough: A Double Blind Randomised Controlled Trial 2014 ·Journal of Allergy and Clinical Immunology ·Saifudin Khalid, Robert Murdoch, Amy Newlands, Kevin Smart, Angela Kelsall, Kimberley Holt, Rachel Dockry, Ashley Woodcock, John A. Smith	1
6	Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients with refractory chronic cough: A double-blind randomized controlled trial 2014 ·Journal of Allergy and Clinical Immunology ·Saifudin Khalid, Robert Murdoch, Amy Newlands, Kevin Smart, Angela Kelsall, Kimberley Holt, Rachel Dockry, Ashley Woodcock, John A. Smith	143
7	TRPV1 inhibition does not prevent cold dry air-elicited symptoms in non-allergic rhinitis 2014 ·International Journal of Clinical Pharmacology and Therapeutics ·Robert Murdoch, Philippe Bareille, Jane Denyer, Amy Newlands, J. Bentley, Kevin Smart, (unknown), Deepen Patel	13
8	Safety, pharmacodynamics (PD) and pharmacokinetics (PK) of darotropium (DARO) and vilanterol (VI) in healthy subjects: Two phase 1 studies 2013 ·Rashmi Mehta, Andrew Preece, Amy Newlands, (unknown), Anthony Cahn	2
9	Inhibition of capsaicin‐driven nasal hyper‐reactivity by SB‐705498, a TRPV1 antagonist 2013 ·British Journal of Clinical Pharmacology ·(unknown), Cornelis M. van Drunen, Jane Denyer, Kevin Smart, Christine Segboer, Ingrid Terreehorst, Amy Newlands, Misba Beerahee, Wytske J. Fokkens, Daphne Tsitoura	19
10	P152 The Impact of a Selective oral TRPV1 Antagonist in Patients with Chronic Cough 2012 ·Thorax ·JA Smith, (unknown), Amy Newlands, Kevin Smart, Saifudin Khalid, Angela Kelsall, Kimberley Holt, Rachel Dockry, Ashley Woodcock	8
11	P154 TRPV1 is not a Target for the Treatment of non-allergic Rhinitis: A Clinical Study 2012 ·Thorax ·(unknown), Philippe Bareille, J. Bentley, Amy Newlands, Kevin Smart, (unknown)	2
12	Pharmacological assessment of the effects of SB-705498 on capsaicin-induced responses in healthy volunteers and patients with non-allergic rhinitis 2011 ·European Respiratory Journal ·(unknown), Christine Segboer, Daphne Tsitoura, Amy Newlands, Philippe Bareille, Jane Denyer, (unknown), (unknown)	1
13	Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPD 2011 ·European Respiratory Journal ·Rashmi Mehta, Amy Newlands, Dennis Kelleher, Andrew Preece, Anthony Cahn, Glenn Crater	7
14	Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults 2011 ·Rashmi Mehta, Kelly Hardes, Anthony Cahn, Amy Newlands, Alison Donald, Andrew Preece, Dennis Kelleher, Glenn Crater	12
15	Safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of GSK573719 inhalation powder in healthy subjects 2011 ·Anthony Cahn, (unknown), Amy Newlands, (unknown), Isabelle Pouliquen, Andrew Preece, Dennis Kelleher, Rashmi Mehta, Ruth Tal‐Singer	8
16	Statistics and Pharmacokinetics in Clinical Pharmacology Studies 2006 ·Amy Newlands, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact